TY - JOUR
T1 - Her3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix
AU - Mizuno, Takaaki
AU - Kojima, Yuki
AU - Yonemori, Kan
AU - Yoshida, Hiroshi
AU - Sugiura, Yukiko
AU - Ohtake, Yohei
AU - Okuma, Hitomi S.
AU - Nishikawa, Tadaaki
AU - Tanioka, Maki
AU - Sudo, Kazuki
AU - Shimomura, Akihiko
AU - Noguchi, Emi
AU - Kato, Tomoyasu
AU - Shimoi, Tatsunori
AU - Uno, Masaya
AU - Ishikawa, Mitsuya
AU - Fujiwara, Yasuhiro
AU - Ohe, Yuichiro
AU - Tamura, Kenji
N1 - Funding Information:
The National Cancer Center Biobank is supported by the National Cancer Center Research and Development Fund, Japan.
Publisher Copyright:
© This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.
PY - 2020/10
Y1 - 2020/10
N2 - Patients with cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) have a poorer prognosis than those with squamous cell carcinoma (SCC). Erb-b2 receptor tyrosine kinase 3 (HER3) is a member of the epidermal growth factor receptor family and its expression is associated with unfavorable prognosis in several cancer types, including SCC of the cervix. As there is limited information on the prognostic value of HER3 for AC and ASC of the cervix, the present study aimed to evaluate the expression of HER3 and its impact on post-operative recurrence in patients with AC and ASC of the cervix. This retrospective study included 39 patients with early-stage AC and ASC who underwent primary surgery between January 1997 and December 2017. Immunohistochemical staining for HER3 was performed on formalin-fixed paraffin-embedded surgical specimens. The possible influence of HER3 expression on disease-free survival (DFS) was studied by using multivariate Cox regression with adjustment for established risk factors of post-operative recur- rence. High expression of HER3 (HER3-high) was detected in 85.1% of cases of AC (23/27) and in 58.3% of cases of ASC (7/12). The median follow-up duration was 63.1 months and Kaplan-Meier analysis indicated that the 5-year DFS rates of patients with AC and ASC of the cervix were 56.7% in patients with HER3-high and 77.8% in patients with HER3-low (log rank, P=0.20). On multivariate analysis, HER3-high [hazard ratio (HR)=6.32, 95% CI: 1.10-36.26, P=0.039), pelvic lymph node metastasis (HR=7.61, 95% CI: 2.07-28.00, P=0.002) and vascular invasion (HR=4.28, 95% CI: 1.12-16.31, P=0.033) were indicated to be independent predictors of DFS. To date, thepresentstudyisthemostcomprehensiveanalysistoevaluate the expression of HER3 in patients with early-stage AC and ASC of the cervix. The results suggested that HER3 overex- pression may be an independent risk factor for post-operative recurrence. However, these results and the prognostic value of HER3 should be confirmed in a larger sample.
AB - Patients with cervical adenocarcinoma (AC) and adenosquamous carcinoma (ASC) have a poorer prognosis than those with squamous cell carcinoma (SCC). Erb-b2 receptor tyrosine kinase 3 (HER3) is a member of the epidermal growth factor receptor family and its expression is associated with unfavorable prognosis in several cancer types, including SCC of the cervix. As there is limited information on the prognostic value of HER3 for AC and ASC of the cervix, the present study aimed to evaluate the expression of HER3 and its impact on post-operative recurrence in patients with AC and ASC of the cervix. This retrospective study included 39 patients with early-stage AC and ASC who underwent primary surgery between January 1997 and December 2017. Immunohistochemical staining for HER3 was performed on formalin-fixed paraffin-embedded surgical specimens. The possible influence of HER3 expression on disease-free survival (DFS) was studied by using multivariate Cox regression with adjustment for established risk factors of post-operative recur- rence. High expression of HER3 (HER3-high) was detected in 85.1% of cases of AC (23/27) and in 58.3% of cases of ASC (7/12). The median follow-up duration was 63.1 months and Kaplan-Meier analysis indicated that the 5-year DFS rates of patients with AC and ASC of the cervix were 56.7% in patients with HER3-high and 77.8% in patients with HER3-low (log rank, P=0.20). On multivariate analysis, HER3-high [hazard ratio (HR)=6.32, 95% CI: 1.10-36.26, P=0.039), pelvic lymph node metastasis (HR=7.61, 95% CI: 2.07-28.00, P=0.002) and vascular invasion (HR=4.28, 95% CI: 1.12-16.31, P=0.033) were indicated to be independent predictors of DFS. To date, thepresentstudyisthemostcomprehensiveanalysistoevaluate the expression of HER3 in patients with early-stage AC and ASC of the cervix. The results suggested that HER3 overex- pression may be an independent risk factor for post-operative recurrence. However, these results and the prognostic value of HER3 should be confirmed in a larger sample.
KW - Biomarker
KW - Cervical cancer
KW - HER3 protein expression
KW - Prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=85089837767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089837767&partnerID=8YFLogxK
U2 - 10.3892/ol.2020.11899
DO - 10.3892/ol.2020.11899
M3 - Article
AN - SCOPUS:85089837767
SN - 1792-1074
VL - 20
JO - Oncology Letters
JF - Oncology Letters
IS - 4
M1 - 11899
ER -
